NeoGenomics, Inc.

Equities

NEO

US64049M2098

Healthcare Facilities & Services

Real-time Estimate Cboe BZX Other stock markets 12:50:53 2024-04-26 pm EDT			5-day change	1st Jan Change
14.3 ^USD	+3.21%		+5.69%	-11.62%

Apr. 18	NeoGenomics, Inc. Announces Senior Leadership Promotions	CI
Apr. 18	NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics	CI

Neogenomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021

May 05, 2021 at 05:33 am EDT

NeoGenomics, Inc. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced total revenue was USD 115.533 million compared to USD 106.030 million a year ago. Operating loss was USD 15.107 million compared to USD 5.293 million a year ago. Net loss was USD 22.114 million compared to USD 6.978 million a year ago. Basic loss per share from continuing operations was USD 0.19 compared to USD 0.07 a year ago.

Latest news about NeoGenomics, Inc.

NeoGenomics, Inc. Announces Senior Leadership Promotions	Apr. 18	CI
NeoGenomics, Inc. Announces Eliminates of Position of Vishal Sikri, President, Advanced Diagnostics	Apr. 18	CI
Piper Sandler Adjusts Price Target on NeoGenomics to $20 From $18, Maintains Overweight Rating	Feb. 26	MT
Goldman Sachs Raises Price Target on NeoGenomics to $19 From $17, Maintains Buy Rating	Feb. 22	MT
Needham Raises NeoGenomics' Price Target to $24 From $21, Keeps Buy Rating	Feb. 21	MT
Traders Await Fed Minutes, Nvidia Earnings as US Equity Futures Drop Pre-Bell	Feb. 21	MT
NeoGenomics Swings to Q4 Adjusted Earnings, Revenue Rises; Issues 2024 Guidance	Feb. 21	MT
Transcript : NeoGenomics, Inc., Q4 2023 Earnings Call, Feb 20, 2024	Feb. 20
NeoGenomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 20	CI
Earnings Flash (NEO) NEOGENOMICS Reports Q4 EPS $0.03, vs. Street Est of $-0.03	Feb. 20	MT
Earnings Flash (NEO) NEOGENOMICS Reports Q4 Revenue $155.6M, vs. Street Est of $152.5M	Feb. 20	MT
NeoGenomics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 20	CI
NeoGenomics, Inc. Provides Earnings Guidance for the Year 2024	Feb. 20	CI
Transcript : NeoGenomics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 05:15 PM	Jan. 08
Neogenomics, Inc. and Concertai, Llc Announce Collaboration to Advance Population-Scale, Definitive Hematological Research & Generative Ai Solutions At Ash 2023	Jan. 08	CI
TD Cowen Cuts Price Target on NeoGenomics to $19 From $22, Maintains Outperform Rating	Dec. 29	MT
BTIG Cuts Price Target on NeoGenomics to $21 From $25, Keeps Buy Rating	Dec. 29	MT
Sector Update: Health Care Stocks Rise in Late Afternoon	Dec. 28	MT
Top Midday Decliners	Dec. 28	MT
NeoGenomics Shares Fall; Company to Appeal Preliminary Injunction in Natera Copyright Battle	Dec. 28	MT
Sector Update: Health Care Stocks Steady Premarket Thursday	Dec. 28	MT
NeoGenomics to Appeal Preliminary Injunction in Natera Copyright Battle	Dec. 28	MT
Sector Update: Health Care Stocks Advance Thursday Afternoon	Dec. 28	MT
Natera Winning RaDaR Preliminary Injunction Bodes Poorly for NeoGenomics, Needham Says	Dec. 28	MT
Natera Wins Preliminary Injunction in Copyright Battle Against NeoGenomics	Dec. 28	MT

Chart NeoGenomics, Inc.

Duration

Period

More charts

Company Profile

NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.

Sector

Healthcare Facilities & Services

Calendar

2024-04-29 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for NeoGenomics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.85 USD

Average target price

21.1 USD

Spread / Average Target

+52.35%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
NEOGENOMICS, INC.	-11.62%	1.77B
SONIC HEALTHCARE LIMITED	-17.89%	8.36B
RADNET, INC.	+40.01%	3.6B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-39.11%	2.73B
SYNLAB AG	-8.06%	2.47B
DR. LAL PATHLABS LIMITED	-7.35%	2.32B
FLEURY S.A.	-18.79%	1.55B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.66%	1.22B
METROPOLIS HEALTHCARE LIMITED	+7.56%	1.09B
ADICON HOLDINGS LIMITED	-15.34%	1.03B

Medical & Diagnostic Laboratories